Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Reduced by Crestline Management LP

Crestline Management LP lowered its stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,860,937 shares of the company's stock after selling 224,687 shares during the period. Crestline Management LP owned approximately 1.28% of Sana Biotechnology worth $4,663,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of Sana Biotechnology by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock valued at $5,206,000 after purchasing an additional 26,601 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Sana Biotechnology by 7.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,108,617 shares of the company's stock valued at $5,068,000 after purchasing an additional 219,498 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Sana Biotechnology by 44.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock valued at $2,538,000 after purchasing an additional 478,596 shares during the period. Boxer Capital Management LLC purchased a new stake in shares of Sana Biotechnology in the fourth quarter valued at approximately $2,518,000. Finally, Northern Trust Corp boosted its stake in shares of Sana Biotechnology by 5.3% in the fourth quarter. Northern Trust Corp now owns 1,188,346 shares of the company's stock valued at $1,937,000 after buying an additional 60,004 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Price Performance

SANA traded up $0.30 on Monday, reaching $2.12. The company's stock had a trading volume of 4,315,898 shares, compared to its average volume of 3,314,599. The stock has a market cap of $476.88 million, a price-to-earnings ratio of -1.51 and a beta of 1.75. Sana Biotechnology, Inc. has a 1 year low of $1.26 and a 1 year high of $9.49. The business's 50 day moving average is $1.93 and its 200 day moving average is $2.47.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. As a group, research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on SANA. Jefferies Financial Group began coverage on Sana Biotechnology in a research note on Friday, March 14th. They issued a "buy" rating and a $7.00 price target on the stock. Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a research note on Tuesday, March 18th. Finally, HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.